The treatment of hepatitis C has been based on specific effective antiviral medications for a number of years. Since future development of resistance cannot be ruled out, alternative treatment options are being researched as well. So-called cell entry inhibitors are considered to be promisi ... more
Prof. Dr. Mark Brönstrup
Helmholtz-Zentrum für Infektionsforschung GmbH
studied Chemistry at Philipps University Marburg (Germany) and London’s Imperial College. He obtained his doctorate in organic chemistry in 1999 from TU Berlin. From 2000 to 2013, he worked at the pharmaceutical company Sanofi in Frankfurt, first as head of a mass spectrometry lab before moving to manage units working on natural product research and biomarkers/diagnostics in diabetes and the division for biomarkers, bioimaging and biological assays. He has been head of the Department of Chemical Biology at the Helmholtz Centre for Infection Research since 2013 and also holds a (W3) professorial chair at Hannover’s Leibniz University.